75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Deutsches Herzzentrum Muenchen
• Collaborator: Technische Universität München
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Patients with chronic aspirin therapy who are treated with percutaneous coronary intervention at least 2 hours after administration of a 600 mg loading dose of clopidogrel

Exclusion Criteria:

• Major alterations of blood count (particularly platelet count < 100x10^9/l, haemoglobin < 10 mg/dl

• Recent bleeding diathesis

• Presence of a hematologic or malignant disorder

• Oral anticoagulation with coumarin derivates

• Use of glycoprotein (GP) IIb/IIIa antagonists during the intervention or during the preceding 14 days

• Therapy with clopidogrel within the last 28 days